SCHEMBL15225534

SCHEMBL15225534

C[C@@]1(OC(=O)c2ccccc2)[C@H](OC(=O)c2ccccc2)[C@@H](COC(=O)c2ccccc2)O[C@H]1n1cc(I)c2c(Cl)ncnc21

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ADK P55263 10/20 0.43
SLC29A1 Q99808 1/20 0.40
GAPDH P04406 1/20 0.35
LMNA P02545 1/20 0.35
ALDH1A1 P00352 2/20 0.35
HRAS P01112 1/20 0.34
NPC1 O15118 1/20 0.34
POLB P06746 2/20 0.33
HTT P42858 1/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13092007 1.00 ADK (0.43) ADKSLC29A1GAPDHLMNAALDH1A1
SCHEMBL16982301 1.00 ADK (0.43) ADKSLC29A1GAPDHLMNAALDH1A1
SCHEMBL2787302 1.00 ADK (0.43) ADKSLC29A1GAPDHLMNAALDH1A1
SCHEMBL21012864 1.00 ADK (0.43) ADKSLC29A1GAPDHLMNAALDH1A1
SCHEMBL14279133 0.91 LMNA (0.37) ADKGAPDHLMNAALDH1A1HRAS
SCHEMBL16480871 0.91 ADK (0.44) ADKSLC29A1GAPDHLMNAALDH1A1
SCHEMBL13021360 0.90 ADK (0.43) ADKSLC29A1GAPDHLMNAALDH1A1
SCHEMBL2785729 0.90 ADK (0.43) ADKSLC29A1GAPDHLMNAALDH1A1
SCHEMBL16496818 0.90 ADK (0.43) ADKSLC29A1GAPDHLMNAALDH1A1
SCHEMBL24539010 0.85 LMNA (0.45) LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10294262-B2 7-deazapurine nucleosides for therapeutic uses INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) 2019-05-21 US disclosed
US-20170240584-A1 NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR,V.V.I. (CZ) 2017-08-24 US disclosed
US-9624257-B2 7-deazapurine nucleosides for therapeutic uses INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. (CZ) 2017-04-18 US disclosed
US-20160318970-A1 NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. (CZ) 2016-11-03 US disclosed
US-9321800-B2 7-deazapurine nucleosides for therapeutic uses GILEAD SCIENCES, INC. (US) 2016-04-26 US disclosed
US-20150218201-A1 NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) 2015-08-06 US disclosed
EP-2421879-B1 NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES ACAD OF SCIENCE CZECH REPUBLIC (CZ) 2013-09-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218201-A1 NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES TPMT, TYMP, ENTPD5 ADK 272/4885SLC29A1 5/4885GAPDH 1763/4885
US-10294262-B2 7-deazapurine nucleosides for therapeutic uses TPMT, TYMP, ENTPD5 ADK 221/4885SLC29A1 6/4885GAPDH 1572/4885
US-20160318970-A1 NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES TPMT, TYMP, ENTPD5 ADK 265/4885SLC29A1 5/4885GAPDH 1704/4885
US-20170240584-A1 NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES TPMT, TYMP, ENTPD5 ADK 272/4885SLC29A1 5/4885GAPDH 1763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.